Majar depression in cancer patient
Conditions
Interventions
antidepressants
safety
Sponsors
Fukuoka University Faculty of Medicine Department of Psychiarty
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Age >= 20 years old 2)Possible oral administration 3)Patient with any cancer 4)Male or female. Inpatient or outpatient. 5)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Brain metastasis confirmed 2)Congnitive impairment 3)Under interferon therapy 4)Bipolar disorder 5)Convulsive disorder or history of convulsive disorder 6)Prior electroconvulsive therapy 7)Dysuria, glaucoma or treatment for elevated intraocular pressure 8)Administration of the monoamine oxidase (MAO) inhibitor within observation period(2 weeks) 9)Hypersensitivity to mirtazapine or duloxetine hydrochloride 10)Pregnancy or lactating woman, woman planning pregnancy 11)Substance or alcohol abuse 180 days prior to administration of investigational drug. 12)Patient ineligible to the study based on investigator's decision.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HAM-D scores between pretreatment baseline and 6-week treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Specific symptoms (pain and nausea) Adverse events | — |
Countries
Japan
Contacts
Public ContactMatsushita michihiko
Fukuoka University Faculty of Medicine Department of Psychiarty
Outcome results
None listed